HRP20040545A2 - Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability - Google Patents

Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability

Info

Publication number
HRP20040545A2
HRP20040545A2 HR20040545A HRP20040545A HRP20040545A2 HR P20040545 A2 HRP20040545 A2 HR P20040545A2 HR 20040545 A HR20040545 A HR 20040545A HR P20040545 A HRP20040545 A HR P20040545A HR P20040545 A2 HRP20040545 A2 HR P20040545A2
Authority
HR
Croatia
Prior art keywords
pharmaceutical compositions
orally active
enhanced bioavailability
taxane derivatives
active taxane
Prior art date
Application number
HR20040545A
Other languages
English (en)
Inventor
B. Bogardus Joseph
K. Perrone Robert
S. Raghavan Krishnaswamy
A. Varia Sailesh
Original Assignee
Bristol-Myers Squibb Company A Delaware (Usa) Corp
Oration
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company A Delaware (Usa) Corp, Oration filed Critical Bristol-Myers Squibb Company A Delaware (Usa) Corp
Publication of HRP20040545A2 publication Critical patent/HRP20040545A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20040545A 2001-12-20 2002-12-12 Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability HRP20040545A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34288901P 2001-12-20 2001-12-20
PCT/US2002/040127 WO2003053350A2 (en) 2001-12-20 2002-12-12 Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability

Publications (1)

Publication Number Publication Date
HRP20040545A2 true HRP20040545A2 (en) 2005-08-31

Family

ID=23343716

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040545A HRP20040545A2 (en) 2001-12-20 2002-12-12 Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability

Country Status (24)

Country Link
US (1) US20030220391A1 (pl)
EP (1) EP1465618A2 (pl)
JP (1) JP2006501134A (pl)
KR (1) KR20040066921A (pl)
CN (1) CN1273130C (pl)
AR (1) AR037951A1 (pl)
AU (1) AU2002361701A1 (pl)
BR (1) BR0215184A (pl)
CA (1) CA2470826A1 (pl)
GE (1) GEP20063806B (pl)
HR (1) HRP20040545A2 (pl)
HU (1) HUP0500843A2 (pl)
IL (1) IL162118A0 (pl)
IS (1) IS7306A (pl)
MX (1) MXPA04005877A (pl)
NO (1) NO20043101L (pl)
PE (1) PE20030742A1 (pl)
PL (1) PL374283A1 (pl)
RS (1) RS52904A (pl)
RU (1) RU2004119557A (pl)
TW (1) TW200302086A (pl)
UY (1) UY27598A1 (pl)
WO (1) WO2003053350A2 (pl)
ZA (1) ZA200404584B (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0307913A (pt) * 2002-02-25 2005-01-11 Lyfjathroun Hf Uso de uma composição, composição farmacêutica para administração nasal, e, métodos para eliciar um efeito terapêutico, profilático e/ou diagnóstico em um mamìfero, para obter um inìcio rápido de um efeito terapêutico, profilático e/ou diagnóstico de uma substância ativa em um mamìfero e para melhorar a biodisponibilidade de um efeito terapêutico, profilático e/ou diagnóstico de uma substância ativa em um mamìfero
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
EP1498120A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
CA2539975C (en) 2003-09-25 2012-11-20 Tapestry Pharmaceuticals, Inc. 9,10-.alpha.,.alpha.-oh-taxane analogs and methods for production thereof
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
WO2006058121A1 (en) * 2004-11-23 2006-06-01 Bristol-Myers Squibb Company Crystalline forms of 3'-tert-butyl-3'-n-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-n-debenzoyl-4-o-methoxycarbonyl-paclitaxel
CN105879114A (zh) * 2005-02-18 2016-08-24 阿布拉西斯生物科学公司 用于整合入医疗装置的疏水性改善的药物
AU2012202903B2 (en) * 2005-02-18 2014-12-11 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices
JP5436856B2 (ja) 2005-07-15 2014-03-05 アンジオケム インコーポレーティッド 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
KR101420445B1 (ko) 2005-08-31 2014-07-16 아브락시스 바이오사이언스, 엘엘씨 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물
WO2007134354A1 (de) * 2006-05-23 2007-11-29 Ebewe Pharma Ges.M.B.H. Nfg. Kg Pharmazeutische formulierung
US11786504B2 (en) 2006-09-28 2023-10-17 Tapestry Pharmaceuticals, Inc. Taxane analogs for the treatment of brain cancer
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
US11873308B2 (en) 2006-11-06 2024-01-16 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
EP1946747A1 (en) * 2007-01-17 2008-07-23 Sandoz AG Pharmaceutical composition of improved stability containing taxane derivatives
WO2008109360A1 (en) * 2007-02-28 2008-09-12 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
MX2010002179A (es) * 2007-08-24 2010-04-27 Stichting Het Nl Kanker I Composicion para el tratamiento de enfermedades neoplasicas.
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
MX2010005198A (es) * 2007-11-12 2010-05-20 Novartis Ag Composiciones liquidas que comprenden valsartan.
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
WO2010133294A2 (de) 2009-05-18 2010-11-25 Boehringer Ingelheim International Gmbh Adapter, inhalationseinrichtung und zerstäuber
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EA026241B1 (ru) 2009-11-25 2017-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Распылитель
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011160932A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nebulizer
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
EP3030298B1 (en) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nebulizer
PL2835146T3 (pl) 2013-08-09 2021-04-06 Boehringer Ingelheim International Gmbh Nebulizator
AU2015257878B2 (en) 2014-05-07 2019-08-08 Boehringer Ingelheim International Gmbh Container, nebulizer and use
EA035261B1 (ru) 2014-05-07 2020-05-21 Бёрингер Ингельхайм Интернациональ Гмбх Небулайзер и контейнер
HUE055604T2 (hu) 2014-05-07 2021-12-28 Boehringer Ingelheim Int Porlasztó
CN103980232A (zh) * 2014-06-05 2014-08-13 北京诺普德医药科技有限公司 10-乙酰基多西紫杉醇及其用途
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
TWI838700B (zh) * 2015-09-30 2024-04-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
CN108066335B (zh) * 2016-11-11 2020-02-21 北京康辰药业股份有限公司 一种含有紫杉醇或其类似物的药物组合物及其制备方法
FR3113238B1 (fr) 2020-08-05 2024-04-05 Gattefosse Sas Utilisation comme excipient, d’un melange de macrogolglyceride laurique et de polyethylene glycol

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
ES2224200T3 (es) * 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
DE69735057T2 (de) * 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen
US5756537A (en) * 1996-11-08 1998-05-26 Parkash S. Gill, M.D., Inc. Regime for paclitaxel in Kaposi's sarcoma patients
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US5980936A (en) * 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
EP1067923A4 (en) * 1997-12-31 2002-11-13 Bristol Myers Squibb Co 2-AROYL-4-ACYL PACLITAXEL (TAXEL) ANALOGS
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
IL144976A0 (en) * 1999-05-17 2002-06-30 Bristol Myers Squibb Co A process for the preparation of paclitaxel
CA2381401A1 (en) * 1999-08-11 2001-02-15 Bristol-Myers Squibb Company Process for the preparation of a paclitaxel c-4 methyl carbonate analog
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6750246B1 (en) * 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
US6916942B2 (en) * 2000-02-03 2005-07-12 Bristol-Myers Squibb Company Process for the preparation of C-4 carbonate taxanes
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
JP2004536026A (ja) * 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof

Also Published As

Publication number Publication date
CA2470826A1 (en) 2003-07-03
AU2002361701A1 (en) 2003-07-09
AR037951A1 (es) 2004-12-22
EP1465618A2 (en) 2004-10-13
WO2003053350A3 (en) 2004-01-15
CN1273130C (zh) 2006-09-06
BR0215184A (pt) 2006-06-06
JP2006501134A (ja) 2006-01-12
ZA200404584B (en) 2005-09-13
US20030220391A1 (en) 2003-11-27
RU2004119557A (ru) 2005-04-20
TW200302086A (en) 2003-08-01
WO2003053350A2 (en) 2003-07-03
NO20043101L (no) 2004-07-19
PL374283A1 (pl) 2005-10-03
KR20040066921A (ko) 2004-07-27
CN1606437A (zh) 2005-04-13
IS7306A (is) 2004-06-10
PE20030742A1 (es) 2003-09-02
GEP20063806B (en) 2006-04-25
HUP0500843A2 (hu) 2005-12-28
IL162118A0 (en) 2005-11-20
RS52904A (sr) 2006-12-15
UY27598A1 (es) 2003-07-31
MXPA04005877A (es) 2004-09-13

Similar Documents

Publication Publication Date Title
HRP20040545A2 (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
EP1461044A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE COMPOUNDS OF VITAMIN D
IL163931A (en) Derivatives of Tetrazycline Compounds Converted by Amino Methyl and Pharmaceutical Preparation Containing Them
PL356358A1 (en) Solid dosage form of someticone for oral administration
AU2003296897A8 (en) Pharmaceutical formulations of camptothecine derivatives
IL159725A0 (en) Pharmaceutical compositions containing benzimidazole derivatives
HUP0201450A3 (en) Solid-state form of celecoxib having enhanced bioavailability, pharmaceutical compositions containing it and their preparation
PL368636A1 (pl) Kompozycje farmaceutyczne, postacie dawkowania i sposoby doustnego podawania epotilonów
SI1390023T1 (sl) Farmacevtske soli spojin 1-fenil-3-dimetilamino-propana
HUP0401642A3 (en) Use of staurosporine derivatives for the preparation of pharmaceutical compositions
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
IL162293A0 (en) Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
IL161693A0 (en) N-adamantylmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation
IL164699A (en) Derivatives of diketohydrazine compounds and pharmaceutical compositions and medicaments containing the compounds as the active ingredient
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
IL156988A0 (en) Pharmaceutical compositions containing epothilone derivatives
IL157128A0 (en) Pharmaceutical compositions containing epothilone derivatives
AU2002346457A8 (en) Pharmaceutical formulations comprising indolinone derivatives
AU2002350386A1 (en) Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
HUP0201394A3 (en) Use of pyrrole derivatives for making pharmaceutical compositions
NO20043007L (no) Farmasoytisk suspensjon for oral administrering
AU2003263480A8 (en) Oral pharmaceutical compositions of fenofibrate having high bioavailability
HK1065948A (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
HUP0303089A3 (en) Stable pharmaceutical form of an anticancer drug

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20061121

Year of fee payment: 5

OBST Application withdrawn